Issue 114 • January 2022

3D printing in drug manufacturing: unlocking future possibilities

Pfizer and Takeda deals put a spotlight on value-based pricing

Can drug repurposing uncover better treatments for UTIs?

In association with

Improving safety for multiple drug regimes 

How safety reporting for treatments involving multiple drugs can be improved to protect patients from harmful drug-drug interactions

In association with

02/24/2024 03:29:00
  • Home | Improving safety for multiple drug regimes 
  • In this issue
  • Contents
  • Curtis Health Caps
  • Astrix
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Owen Mumford Company Insight
  • Owen Mumford
  • Comment
  • Use of AI in the fight against Covid-19 shows mixed results
  • What does Ireland’s tax hike mean for pharma?
  • Chinese review designations lag behind US and EU
  • The business benefits of text mining in life sciences
  • Mettler Toledo
  • HOF Sonderanlagenbau
  • In Depth
  • Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs
  • The challenges of multiple drugs safety reporting
  • 3D printing in drug manufacturing: unlocking future possibilities
  • Can drug repurposing uncover better treatments for UTIs?
  • Pfizer and Takeda deals put a spotlight on value-based pricing
  • Lethal injection: can pharma kill the death penalty?
  • Mimotopes Company Insight
  • Mimotopes
  • In Data
  • Middle-income countries’ healthcare sectors to keep rising through to 2024
  • Data analytics hiring levels in clinical trial operations rose in October
  • Industrial automation innovation in pharma rebounded in the last quarter
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Yearbook
  • SHL Medical
  • Dr. Paul Lohmann Company Insight
  • Dr. Paul Lohmann
  • Novo Nordisk
  • Nipro
  • Events
  • Next issue
12/15/2021 00:00:00